WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Stock

$68.26+1.93 (+2.91%)
Updated Mar 27, 2024
AZN Price
$68.26
Fair Value Price
$93.61
Market Cap
$211.63B
52 Week Low
$60.47
52 Week High
$76.56
P/E
35.55x
P/B
5.41x
P/S
4.56x
PEG
0.79x
Dividend Yield
2.12%
Revenue
$45.81B
Earnings
$5.96B
Gross Margin
82%
Operating Margin
18.6%
Profit Margin
13%
Debt to Equity
1.58
Operating Cash Flow
$10B
Beta
0.55
Next Earnings
Apr 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AZN Overview

AstraZeneca PLC, is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. Its offers products for oncology, cardiovascular, renal, and metabolism diseases, respiratory and immunology, rare diseases, respiratory syncytial virus, Influenza, schizophrenia bipolar disease, gastroenterology, and COVID-19. AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, U.K.

Zen Score

Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AZN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AZN ($68.26) is undervalued by 27.08% relative to our estimate of its Fair Value price of $93.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AZN ($68.26) is significantly undervalued by 27.08% relative to our estimate of its Fair Value price of $93.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AZN ($68.26) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AZN due diligence checks available for Premium users.

Be the first to know about important AZN news, forecast changes, insider trades & much more!

AZN News

Valuation

AZN fair value

Fair Value of AZN stock based on Discounted Cash Flow (DCF)
Price
$68.26
Fair Value
$93.61
Undervalued by
27.08%
AZN ($68.26) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZN ($68.26) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZN ($68.26) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AZN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
35.55x
Industry
160.12x
Market
44.45x
AZN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AZN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

AZN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.41x
Industry
6.14x
AZN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AZN price to earnings growth (PEG)

For valuing profitable companies with growth potential
AZN is good value based... subscribe to Premium to read more.
PEG Value Valuation

AZN's financial health

Profit margin

Revenue
$12.0B
Net Income
$960.0M
Profit Margin
8%
AZN's Earnings (EBIT) of $8.52B... subscribe to Premium to read more.
Interest Coverage Financials
AZN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$101.1B
Liabilities
$62.0B
Debt to equity
1.58
AZN's short-term liabilities ($30.54B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZN's long-term liabilities ($31.41B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.4B
Investing
-$1.1B
Financing
-$291.0M
AZN's operating cash flow ($10.35B)... subscribe to Premium to read more.
Debt Coverage Financials

AZN vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
AZN$211.63B+2.91%35.55x5.41x
NVS$195.98B+0.64%13.41x4.20x
PFE$156.87B+0.69%73.11x1.76x
AMGN$153.43B+1.61%22.79x24.62x
SNY$125.32B-0.42%21.38x1.57x

Astrazeneca Stock FAQ

What is Astrazeneca's quote symbol?

(NASDAQ: AZN) Astrazeneca trades on the NASDAQ under the ticker symbol AZN. Astrazeneca stock quotes can also be displayed as NASDAQ: AZN.

If you're new to stock investing, here's how to buy Astrazeneca stock.

What is the 52 week high and low for Astrazeneca (NASDAQ: AZN)?

(NASDAQ: AZN) Astrazeneca's 52-week high was $76.56, and its 52-week low was $60.47. It is currently -10.84% from its 52-week high and 12.88% from its 52-week low.

How much is Astrazeneca stock worth today?

(NASDAQ: AZN) Astrazeneca currently has 1,550,162,626 outstanding shares. With Astrazeneca stock trading at $68.26 per share, the total value of Astrazeneca stock (market capitalization) is $211.63B.

Astrazeneca stock was originally listed at a price of $18.00 in Dec 31, 1997. If you had invested in Astrazeneca stock at $18.00, your return over the last 26 years would have been 279.22%, for an annualized return of 5.26% (not including any dividends or dividend reinvestments).

How much is Astrazeneca's stock price per share?

(NASDAQ: AZN) Astrazeneca stock price per share is $68.26 today (as of Mar 27, 2024).

What is Astrazeneca's Market Cap?

(NASDAQ: AZN) Astrazeneca's market cap is $211.63B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Astrazeneca's market cap is calculated by multiplying AZN's current stock price of $68.26 by AZN's total outstanding shares of 1,550,162,626.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.